EUVIMEDEUVIMED entdecken
Crossref

Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis

Dominique O Farrera, Kayla L Frost, Joseph L Jilek, Paxton A Sample, Jailyn M Izu, Mina M Alaaldin, Paige Lindberg, Max M Maloney, David Rodrigues, Emi Yamaguchi, Sangwoo Ryu, Yi-An Bi und 17 weitere

Drug Metabolism and Disposition · 2026-08 · 54 (8) · 100351

DOI: 10.1016/j.dmd.2026.100351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-08. Verfasst von Dominique O Farrera und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona. Hauptthemen laut MEDLINE: Ezetimibe, Non-alcoholic Fatty Liver Disease, Glucuronides, Metabolic Diseases. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Bristol Myers Squibb, National Institute of Environmental Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with an urgent need for reliable, noninvasive biomarkers that can serve as reasonably likely surrogate endpoints, as diagnosis remains limited by the invasiveness of liver biopsy and the inaccuracy of existing noninvasive tests. MASH disrupts hepatic and renal transporter expression and function, leading to increased systemic retention of drug substrates. Because ezetimibe-glucuronide (EZEG) is a substrate of transporters altered in MASH, we evaluated whether EZEG could serve as a noninvasive, mechanism-based exogenous diagnostic function test. Plasma and urine EZEG concentrations were quantified by liquid chromatography-tandem mass spectrometry in biopsy-confirmed patients with nonalcoholic fatty liver disease activity scores (NAS) of 0-5 after administration of a 1 mg subtherapeutic dose of ezetimibe. Patients with MASH (NAS = 5, n = 8) exhibited approximately 4.5-fold higher plasma EZEG concentrations than non-MASH individuals (NAS 0-4, n = 45), demonstrating excellent discrimination with an area under the receiver operating characteristic curve of 0.92 (95% CI, 0.79-1.00) using the 60-minute postdose concentration. Plasma EZEG was strongly associated with hepatocyte ballooning, the U.S. Food and Drug Administration-defining and most difficult-to-detect histologic feature of MASH, supporting mechanistic specificity. In contrast, urinary EZEG excretion showed only modest increases and poor diagnostic discrimination. These findings indicate that MASH-associated transporter dysfunction leads to systemic EZEG accumulation, supporting its use as a mechanism-based diagnostic function test and a promising noninvasive strategy for early detection and disease stratification. SIGNIFICANCE STATEMENT: Metabolic dysfunction-associated steatohepatitis (MASH) lacks reliable noninvasive tests for diagnosis and therapeutic development. This study demonstrates that plasma ezetimibe-glucuronide, measured after a subtherapeutic ezetimibe dose, sensitively detects MASH-associated transporter dysfunction and strongly correlates with hepatocyte ballooning, the defining histologic feature of MASH. This mechanism-based probe-drug approach provides a highly discriminative, noninvasive strategy to support early disease detection and patient stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EzetimibeNon-alcoholic Fatty Liver DiseaseGlucuronidesMetabolic DiseasesFatty LiverHumansMaleFemaleMiddle AgedBiomarkersLiverAdultTandem Mass SpectrometryAzetidines

Stichwörter der Autor:innen

Drug transportersEzetimibe-glucuronideHepatocyte ballooningMetabolic dysfunction–associated steatohepatitisNoninvasive biomarker

Substanzen

EzetimibeGlucuronidesezetimibe glucuronideBiomarkersAzetidines

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona.
  • Medicine Design, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut.
  • BIO5 Institute, University of Arizona, Tucson, Arizona.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
  • Department of Surgery, College of Medicine, University of Arizona, Tucson, Arizona.
  • Thomas Boyer Liver Institute and Department of Medicine, College of Medicine, University of Arizona, Tucson, Arizona.

Förderung

  • Bristol Myers Squibb
  • National Institute of Environmental Health Sciences

Zitieren

APA

Farrera, D. O., Frost, K. L., Jilek, J. L., Sample, P. A., Izu, J. M., Alaaldin, M. M., Lindberg, P., Maloney, M. M., Rodrigues, D., Yamaguchi, E., Ryu, S., Bi, Y. A., West, M., Mathialagan, S., Lazzaro, S., Rabe, B., Nguyen, A. P., Ho, K., Messenger, S., …, & Cherrington, N. J. (2026). Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis. Drug Metabolism and Disposition, 54(8), 100351. https://doi.org/10.1016/j.dmd.2026.100351

Vancouver

Farrera DO, Frost KL, Jilek JL, Sample PA, Izu JM, Alaaldin MM, et al. Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis. Drug Metabolism and Disposition. 2026;54(8):100351. doi:10.1016/j.dmd.2026.100351

BibTeX
@article{Farrera2026,
  author = {Farrera, Dominique O and Frost, Kayla L and Jilek, Joseph L and Sample, Paxton A and Izu, Jailyn M and Alaaldin, Mina M and Lindberg, Paige and Maloney, Max M and Rodrigues, David and Yamaguchi, Emi and Ryu, Sangwoo and Bi, Yi-An and West, Mark and Mathialagan, Sumathy and Lazzaro, Sarah and Rabe, Brooke and Nguyen, Aiden-Hung P and Ho, Katherine and Messenger, Susie and Rahimi, Ahmad Omid and Akhbari, Ryan and Säll, Carolina and Klimecki, Walter and Paine, Mary F and Wright, Stephen H and Billheimer, Dean and Block, Geoffrey and Ghaderi, Iman and Cherrington, Nathan J},
  title = {Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {8},
  pages = {100351},
  doi = {10.1016/j.dmd.2026.100351}
}
Kostenlos starten →